ASX Penny Stocks To Watch In March 2025

The Australian stock market recently saw the ASX200 close down by 0.4% at 7,828 points, with Health Care and Telecommunication sectors showing resilience while Utilities and Real Estate lagged behind. In this context, penny stocks—often seen as a niche investment area—still hold potential for investors seeking growth opportunities in smaller or newer companies. Despite their somewhat outdated label, these stocks can offer significant returns when backed by strong financial health; we'll explore three such promising options on the ASX that might capture investor interest.

Top 10 Penny Stocks In Australia

Click here to see the full list of 979 stocks from our ASX Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Dimerix (ASX:DXB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dimerix Limited is an Australian biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs, with a market cap of A$273.60 million.

Operations: Dimerix generates revenue from its biotechnology segment, amounting to A$0.74 million.

Market Cap: A$273.6M

Dimerix Limited, an Australian biopharmaceutical company, remains pre-revenue with earnings of A$0.74 million and a market cap of A$273.60 million. Despite being debt-free and having short-term assets exceeding liabilities, the company is unprofitable with a negative return on equity. Recent volatility in its share price highlights investment risks common in penny stocks. Dimerix has secured an exclusive agreement to commercialize DMX-200 in Japan, potentially enhancing future prospects despite current financial challenges. The company's cash runway exceeds one year under stable conditions but could be less than a year if free cash flow continues to decline at historical rates.

• Click to explore a detailed breakdown of our findings in Dimerix's financial health report.
• Assess Dimerix's previous results with our detailed historical performance reports.

Imugene (ASX:IMU)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Imugene Limited is a clinical stage immuno-oncology company based in Australia, focused on developing immunotherapies to activate the immune system of cancer patients for tumour treatment, with a market cap of A$298.30 million.

Operations: The company generates revenue from the research, development, and commercialisation of health technologies amounting to -A$1.84 million.

Market Cap: A$298.3M

Imugene Limited, a pre-revenue biotech firm with a market cap of A$298.30 million, faces challenges typical of penny stocks. Despite having short-term assets (A$81.6M) exceeding both its short and long-term liabilities, the company remains unprofitable with losses increasing over five years. Recent executive changes bring experienced leadership in finance with Darren Keamy as CFO and Company Secretary, potentially strengthening financial strategies. The company's cash runway is limited to four months based on free cash flow estimates but has been bolstered by recent capital raises through convertible notes and warrants issuance totaling A$20 million.

• Click here and access our complete financial health analysis report to understand the dynamics of Imugene.
• Gain insights into Imugene's outlook and expected performance with our report on the company's earnings estimates.

Judo Capital Holdings (ASX:JDO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Judo Capital Holdings Limited, through its subsidiaries, provides banking products and services to small and medium businesses in Australia, with a market cap of A$2.07 billion.

Operations: The company generates revenue of A$325.5 million from its banking operations catering to small and medium enterprises in Australia.

Market Cap: A$2.07B

Judo Capital Holdings, with a market cap of A$2.07 billion, operates in the SME banking sector and is not pre-revenue. The company has experienced negative earnings growth over the past year (-22%), which contrasts with its previous five-year profitability trend. Despite this setback, Judo maintains high-quality earnings and a stable weekly volatility of 4%. Its bad loans ratio is appropriate at 1.2%, supported by a sufficient allowance for bad loans at 111%. The company's funding structure is primarily low-risk, relying heavily on customer deposits (72% of liabilities), though its Loans to Deposits ratio remains high at 128%.

• Take a closer look at Judo Capital Holdings' potential here in our financial health report.
• Evaluate Judo Capital Holdings' prospects by accessing our earnings growth report.

Summing It All Up

• Navigate through the entire inventory of 979 ASX Penny Stocks here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com